Recent

% | $
Quotes you view appear here for quick access.

Perfect World Co., Ltd. (PWRD) Message Board

  • stockteam1 stockteam1 May 23, 2011 5:04 PM Flag

    PWRD BUY BUY BUY

    BEIJING, May 23, 2011 /PRNewswire-Asia/ -- Perfect World Co., Ltd. (NASDAQ:PWRD - News) ("Perfect World" or the "Company"), a leading online game developer and operator based in China, today announced its unaudited financial results for the first quarter ended March 31, 2011.

    (Logo: http://photos.prnewswire.com/prnh/20090416/CNTH023LOGO )

    First Quarter 2011 Highlights(1)

    * Total revenues were RMB721.0 million (USD110.1 million), as compared to RMB593.0 million in 4Q10 and RMB625.0 million in 1Q10
    * Gross profit was RMB612.9 million (USD93.6 million), as compared to RMB482.3 million in 4Q10 and RMB537.9 million in 1Q10
    * Operating profit was RMB286.8 million (USD43.8 million), as compared to RMB122.8 million in 4Q10 and RMB323.2 million in 1Q10. Non-GAAP operating profit(2) was RMB312.5 million (USD47.7 million), as compared to RMB147.3 million in 4Q10 and RMB344.9 million in 1Q10
    * Net income attributable to the Company's shareholders was RMB263.7 million (USD40.3 million), as compared to RMB125.2 million in 4Q10 and RMB305.2 million in 1Q10. Non-GAAP net income attributable to the Company's shareholders(2) was RMB289.5 million (USD44.2 million), as compared to RMB149.7 million in 4Q10 and RMB327.0 million 1Q10
    * Basic and diluted earnings per ADS(3) were RMB5.25 (USD0.80) and RMB4.99 (USD0.76), respectively, as compared to RMB2.50 and RMB2.36, respectively, in 4Q10, and RMB6.12 and RMB5.75, respectively, in 1Q10. Non-GAAP basic and diluted earnings per ADS(2) were RMB5.76 (USD0.88) and RMB5.48 (USD0.84), respectively, as compared to RMB2.98 and RMB2.82, respectively, in 4Q10, and RMB6.56 and RMB6.16, respectively, in 1Q10
    * Launched Open Beta Testing for "Empire of the Immortals" on March 22, 2011

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
PWRD
20.170.00(0.00%)Jul 28 4:00 PMEDT